Logo image of BIVI

BIOVIE INC (BIVI) Stock Fundamental Analysis

NASDAQ:BIVI - US09074F4054 - Common Stock

1.52 USD
+0.04 (+2.7%)
Last: 8/29/2025, 8:08:23 PM
1.47 USD
-0.05 (-3.29%)
After Hours: 8/29/2025, 8:08:23 PM
Fundamental Rating

2

Overall BIVI gets a fundamental rating of 2 out of 10. We evaluated BIVI against 545 industry peers in the Biotechnology industry. While BIVI seems to be doing ok healthwise, there are quite some concerns on its profitability. BIVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIVI had negative earnings in the past year.
In the past year BIVI has reported a negative cash flow from operations.
BIVI had negative earnings in each of the past 5 years.
In the past 5 years BIVI always reported negative operating cash flow.
BIVI Yearly Net Income VS EBIT VS OCF VS FCFBIVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -78.52%, BIVI is not doing good in the industry: 66.36% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -88.75%, BIVI is in line with its industry, outperforming 49.54% of the companies in the same industry.
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROIC N/A
ROA(3y)-134.6%
ROA(5y)-1013.34%
ROE(3y)-417.04%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIVI Yearly ROA, ROE, ROICBIVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

BIVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIVI Yearly Profit, Operating, Gross MarginsBIVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BIVI has been increased compared to 1 year ago.
BIVI has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BIVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BIVI Yearly Shares OutstandingBIVI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BIVI Yearly Total Debt VS Total AssetsBIVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

BIVI has an Altman-Z score of -18.84. This is a bad value and indicates that BIVI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BIVI (-18.84) is worse than 82.82% of its industry peers.
There is no outstanding debt for BIVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.84
ROIC/WACCN/A
WACCN/A
BIVI Yearly LT Debt VS Equity VS FCFBIVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M -40M

2.3 Liquidity

A Current Ratio of 9.31 indicates that BIVI has no problem at all paying its short term obligations.
BIVI's Current ratio of 9.31 is fine compared to the rest of the industry. BIVI outperforms 79.16% of its industry peers.
A Quick Ratio of 9.31 indicates that BIVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.31, BIVI is in the better half of the industry, outperforming 79.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.31
Quick Ratio 9.31
BIVI Yearly Current Assets VS Current LiabilitesBIVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

BIVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.03%, which is quite impressive.
EPS 1Y (TTM)78.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BIVI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.26%
EPS Next 2Y41.24%
EPS Next 3Y26.76%
EPS Next 5Y17.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIVI Yearly Revenue VS EstimatesBIVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 20M 40M 60M 80M 100M
BIVI Yearly EPS VS EstimatesBIVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIVI Price Earnings VS Forward Price EarningsBIVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIVI Per share dataBIVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 26.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.24%
EPS Next 3Y26.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOVIE INC

NASDAQ:BIVI (8/29/2025, 8:08:23 PM)

After market: 1.47 -0.05 (-3.29%)

1.52

+0.04 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)09-29 2025-09-29/amc
Inst Owners5.58%
Inst Owner Change8.8%
Ins Owners0.84%
Ins Owner Change0%
Market Cap11.45M
Analysts82.86
Price Target56.1 (3590.79%)
Short Float %N/A
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.18%
Min EPS beat(2)-181.86%
Max EPS beat(2)13.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-21.14
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0
BVpS2.78
TBVpS2.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-134.6%
ROA(5y)-1013.34%
ROE(3y)-417.04%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.31
Quick Ratio 9.31
Altman-Z -18.84
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.46%
EPS Next Y96.26%
EPS Next 2Y41.24%
EPS Next 3Y26.76%
EPS Next 5Y17.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.99%
OCF growth 3YN/A
OCF growth 5YN/A